Credit Suisse Downgrades Pfizer (PFE)

Credit Suisse Downgrades Pfizer (PFE)


Credit Suisse reported on Thursday that they have lowered their rating on biopharmaceutical company, Pfizer Inc.(PFE).

The firm has downgraded PFE from “Outperform” to “Neutral,” and has given the company a $29 price target. This price target suggests a 6% increase from the stock’s current price of $27.20.

Pfizer shares were down 19 cents, or -0.70% during Thursday morning trading. The stock has increased 29% in the past year.

The Bottom Line
Shares of Pfizer Inc.(PFE) have a 3.53% yield, based on Thursday morning’s price of $27.20.

Pfizer Inc.(PFE) is a “Recommended” dividend stock at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today